Table 3.
History of screening and treatment by baseline cotest result among individuals in IRIS cohort.
| Baseline cotest result | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| High-grade+ | LSIL | ASC-US | NILM | ||||||||
| Participant clinical historya | IRIS cohort | % of IRIS cohort | % of KPNC populationa,b | HPV+ | HPV− | HPV+ | HPV− | HPV+ | HPV− | HPV+ | HPV− |
| Total | 77,920 | 100% | 100% | 3,449 | 1,031 | 11,678 | 1,272 | 15,984 | 7,912 | 23,846 | 12,748 |
| Routine screening | 30,520 | 39.2% | 58.4% | 722 | 427 | 3,418 | 506 | 4,824 | 3,894 | 8,964 | 7,765 |
| (previous screen negative) | 20.9% | 41.4% | 29.3% | 39.8% | 30.2% | 49.2% | 37.6% | 60.9% | |||
| Early (≤30 months) | 4,473 | 5.7% | 14.6% | 87 | 54 | 600 | 66 | 782 | 568 | 1,371 | 945 |
| 2.5% | 5.2% | 5.1% | 5.2% | 4.9% | 7.2% | 5.7% | 7.4% | ||||
| Timely (≤42 months) | 17,630 | 22.6% | 37.7% | 349 | 267 | 1,801 | 316 | 2,646 | 2,316 | 4,941 | 4,994 |
| 10.1% | 25.9% | 15.4% | 24.8% | 16.6% | 29.3% | 20.7% | 39.2% | ||||
| Late (>42 months) | 8,417 | 10.8% | 7.1% | 286 | 106 | 1,017 | 124 | 1,396 | 1,010 | 2,652 | 1,826 |
| 8.3% | 10.3% | 8.7% | 9.7% | 8.7% | 12.8% | 11.1% | 14.3% | ||||
| Previous screen abnormal | 4,854 | 6.2% | 3.3% | 258 | 16 | 812 | 56 | 1,227 | 229 | 2,052 | 204 |
| 7.5% | 1.6% | 7.0% | 4.4% | 7.7% | 2.9% | 8.6% | 1.6% | ||||
| Postcolposcopy | 17,130 | 22.0% | 10.3% | 892 | 245 | 3,302 | 305 | 4,465 | 1,551 | 4,985 | 1,385 |
| 25.9% | 23.8% | 28.3% | 24.0% | 27.9% | 19.6% | 20.9% | 10.9% | ||||
| Recent (<42 months) | 11,225 | 14.4% | 3.2% | 659 | 151 | 2,545 | 182 | 3,191 | 748 | 3,255 | 494 |
| 19.1% | 14.6% | 21.8% | 14.3% | 20.0% | 9.5% | 13.7% | 3.9% | ||||
| Distant (42+ months) | 5,905 | 7.6% | 7.1% | 233 | 94 | 757 | 123 | 1,274 | 803 | 1,730 | 891 |
| 6.8% | 9.1% | 6.5% | 9.7% | 8.0% | 10.1% | 7.3% | 7.0% | ||||
| Posttreatment | 4,095 | 5.3% | 2.5% | 392 | 130 | 631 | 83 | 807 | 453 | 1,133 | 466 |
| 11.4% | 12.6% | 5.4% | 6.5% | 5.0% | 5.7% | 4.8% | 3.7% | ||||
| Unknown clinical history | 21,321 | 27.4% | 25.5% | 1,185 | 213 | 3,515 | 322 | 4,661 | 1,785 | 6,712 | 2,928 |
| 34.4% | 20.7% | 30.1% | 25.3% | 29.2% | 22.6% | 28.1% | 23.0% | ||||
Note: High-grade+ includes atypical glandular cells of undetermined significance (AGUS), atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion (ASC-H), HSILs, and carcinoma.
Abbreviation: NILM, negative for intraepithelial lesion or malignancy.
aClinical history at first cotest during period between January 2016 and August 2018.
bDistribution at KPNC for individuals with one or more cotest results between January 2016 and August 2018.